Christophe Weber, the first foreign-born chief executive officer of Japan’s Takeda Pharmaceutical Co., last month inked a $62 billion takeover of rare-disease drugmaker Shire Plc. The deal will reshape the 237-year-old, Osaka-based company into a global powerhouse. In a recent interview in Manhattan, the French-born CEO talked about exciting areas of research and the potential of China. (This interview has been edited and condensed for clarity.)
What will China’s future be in the pharmaceutical industry?